دورية أكاديمية
أعرض في EDS

Drug discovery and mutant p53.

التفاصيل البيبلوغرافية
العنوان: Drug discovery and mutant p53.
المؤلفون: Maslon MM; University of Edinburgh, Institute of Genetics and Molecular Medicine, Cell Signalling Unit, Cancer Research UK p53 Signal Transduction Group, Edinburgh EH4 2XR, UK., Hupp TR
المصدر: Trends in cell biology [Trends Cell Biol] 2010 Sep; Vol. 20 (9), pp. 542-55. Date of Electronic Publication: 2010 Jul 24.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't; Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Science Publishers Country of Publication: England NLM ID: 9200566 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3088 (Electronic) Linking ISSN: 09628924 NLM ISO Abbreviation: Trends Cell Biol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Cambridge, UK : Elsevier Science Publishers, c1991-
مواضيع طبية MeSH: Drug Discovery*, Tumor Suppressor Protein p53/*genetics, Humans ; Mutation ; Neoplasms/genetics ; Proto-Oncogene Proteins c-mdm2/chemistry ; Proto-Oncogene Proteins c-mdm2/metabolism ; Signal Transduction ; Tumor Suppressor Protein p53/chemistry ; Tumor Suppressor Protein p53/metabolism
مستخلص: Missense mutations in the p53 gene are commonly selected for in developing human cancer cells. These diverse mutations in p53 can inactivate its normal sequence-specific DNA-binding and transactivation function, but these mutations can also stabilize a mutant form of p53 with pro-oncogenic potential. Recent multi-disciplinary advances have demonstrated exciting and unexpected potential in therapeutically targeting the mutant p53 pathway, including: the development of biophysical models to explain how mutations inactivate p53 and strategies for refolding and reactivation of mutant p53, the ability of mutant p53 protein to escape MDM2-mediated degradation in human cancers, and the growing 'interactome' of mutant p53 that begins to explain how the mutant p53 protein can contribute to diverse oncogenic and pro-metastatic signaling. Our rapidly accumulating knowledge on mutant p53-signaling pathways will facilitate drug discovery programmes in the challenging area of protein-protein interactions and mutant protein conformational control.
(Copyright 2010. Published by Elsevier Ltd.)
Number of References: 116
معلومات مُعتمدة: C483/A6354 United Kingdom Cancer Research UK; C483/A8033 United Kingdom Cancer Research UK
المشرفين على المادة: 0 (Tumor Suppressor Protein p53)
EC 2.3.2.27 (Proto-Oncogene Proteins c-mdm2)
تواريخ الأحداث: Date Created: 20100727 Date Completed: 20100930 Latest Revision: 20161125
رمز التحديث: 20240628
DOI: 10.1016/j.tcb.2010.06.005
PMID: 20656489
قاعدة البيانات: MEDLINE
الوصف
تدمد:1879-3088
DOI:10.1016/j.tcb.2010.06.005